Diabetes in post genomic era: promises to discover biomarkers and new drug targets.
The complementary disciplines of genomics and proteomics offer better insights into the molecular mechanisms of diseases. Whilst genomics hunts for defining our static genetic substrate, proteomics explores the structure and function of proteins expressed by a cell or tissue type under specified conditions. In the past decade, proteomics has been revolutionized by the application of techniques such as two-dimensional gel electrophoresis (2-DGE), mass spectrometry and protein arrays. These techniques have tremendous potential for biomarker development, target validation, diagnosis, prognosis, and optimization of treatment in medical care, especially in the field of diabetes. This mini review will highlight the contributions of proteomic technologies towards the discovery of potentially new biomarkers for pathophysiological mechanisms and clinical outcome of diabetes.